Eisai has bolstered its U.S. neurology leadership team by snagging executives from Sanofi and Pfizer to create and drive commercial strategies for the company.

One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of different categories and ranked in a cumulative […]

(Reuters Health) – People with early Alzheimer’s disease who consumed light to moderate amounts of alcohol every day were less likely to die during a recent one-year study, researchers found. “These results are somewhat surprising because Alzheimer´s disease is a neurodegenerative disease and we know that alcohol can have harmful effects on the brain,” said […]

With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]

Analysts are again checking the tea leaves and analyzing the stars to try and understand what Cambridge, Mass.-based Biogen, Inc. (BIIB) has in the works. Now the Boston Business Journal reports that despite the company’s plans to cut 11 percent of its workforce, it also appears to be planning to expand its Kendal Square facilities […]

Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and […]

November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff   After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s strategy. On Oct. 21, 2015, Biogen released its third-quarter financials which included $2.8 billion in revenues, an 11 percent increase compared to the third quarter […]

(Reuters Health) – The U.S. death rate for all causes is continuing to decline, aided by drops in fatalities from leading causes like heart disease, cancer, stroke, diabetes and accidents, new research finds. Between 1969 and 2013, the death rate for all causes declined 43 percent from about 1,279 people for each 100,000 individuals in […]